Suppr超能文献

树突状细胞在前列腺肿瘤发生的早期阶段就开始编程非免疫原性的前列腺特异性T细胞反应。

Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis.

作者信息

Mihalyo Marianne A, Hagymasi Adam T, Slaiby Aaron M, Nevius Erin E, Adler Adam J

机构信息

Center for Immunotherapy of Cancer and Infectious Diseases and Department of Immunology, University of Connecticut Health Center, Farmington, Connecticut 06030, USA.

出版信息

Prostate. 2007 Apr 1;67(5):536-46. doi: 10.1002/pros.20549.

Abstract

BACKGROUND

Prostate cancer promotes the development of T cell tolerance towards prostatic antigens, potentially limiting the efficacy of prostate cancer vaccines targeting these antigens. Here, we sought to determine the stage of disease progression when T cell tolerance develops, as well as the role of steady state dendritic cells (DC) and CD4(+)CD25(+) T regulatory cells (Tregs) in programming tolerance.

METHODS

The response of naïve HA-specific CD4(+) T cells were analyzed following adoptive transfer into Pro-HA x TRAMP transgenic mice harboring variably-staged HA-expressing prostate tumors on two genetic backgrounds that display different patterns and kinetics of tumorigenesis. The role of DC and Tregs in programming HA-specific CD4 cell responses were assessed via depletion.

RESULTS

HA-specific CD4 cells underwent non-immunogenic responses at all stages of tumorigenesis in both genetic backgrounds. These responses were completely dependent on DC, but not appreciably influenced by Tregs.

CONCLUSIONS

These results suggest that tolerogenicity is an early and general property of prostate tumors.

摘要

背景

前列腺癌促进T细胞对前列腺抗原产生耐受性,这可能会限制针对这些抗原的前列腺癌疫苗的疗效。在此,我们试图确定T细胞耐受性产生时疾病进展的阶段,以及稳态树突状细胞(DC)和CD4(+)CD25(+) T调节细胞(Tregs)在诱导耐受性中的作用。

方法

将幼稚的HA特异性CD4(+) T细胞过继转移到Pro-HA x TRAMP转基因小鼠中后,分析其反应,这些小鼠在两种遗传背景上携带不同分期的表达HA的前列腺肿瘤,这两种背景显示出不同的肿瘤发生模式和动力学。通过清除法评估DC和Tregs在调节HA特异性CD4细胞反应中的作用。

结果

在两种遗传背景的肿瘤发生的所有阶段,HA特异性CD4细胞均发生非免疫原性反应。这些反应完全依赖于DC,但不受Tregs的明显影响。

结论

这些结果表明,耐受性是前列腺肿瘤的一种早期和普遍特性。

相似文献

2
Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
Cancer Res. 2008 Jan 1;68(1):292-300. doi: 10.1158/0008-5472.CAN-07-2429.

引用本文的文献

1
The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors.
Explor Target Antitumor Ther. 2022;3(5):694-718. doi: 10.37349/etat.2022.00108. Epub 2022 Oct 31.
2
Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer.
Front Immunol. 2021 Mar 29;12:641307. doi: 10.3389/fimmu.2021.641307. eCollection 2021.
4
Regulatory considerations for clinical development of cancer vaccines.
Hum Vaccin Immunother. 2014;10(11):3409-14. doi: 10.4161/21645515.2014.982999.
5
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.
J Transl Med. 2013 Apr 4;11:89. doi: 10.1186/1479-5876-11-89.
6
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.
Oncoimmunology. 2013 Jan 1;2(1):e22837. doi: 10.4161/onci.22837.
7
CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion.
Immunol Cell Biol. 2013 Feb;91(2):173-83. doi: 10.1038/icb.2012.74. Epub 2013 Jan 8.
8
Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model.
Prostate. 2012 Apr;72(5):514-22. doi: 10.1002/pros.21453. Epub 2011 Jul 14.
9
Prostate cancer as a model for tumour immunotherapy.
Nat Rev Immunol. 2010 Aug;10(8):580-93. doi: 10.1038/nri2817.

本文引用的文献

1
Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones.
Curr Cancer Drug Targets. 2007 Feb;7(1):3-14. doi: 10.2174/156800907780006931.
2
Therapeutic cancer vaccines.
Curr Opin Immunol. 2006 Apr;18(2):201-5. doi: 10.1016/j.coi.2006.01.009. Epub 2006 Feb 7.
3
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43. doi: 10.1073/pnas.0509182102. Epub 2005 Dec 12.
4
Dendritic cells maximize the memory CD8 T cell response to infection.
Immunity. 2005 May;22(5):561-70. doi: 10.1016/j.immuni.2005.03.005.
5
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.
Cancer Cell. 2005 Mar;7(3):239-49. doi: 10.1016/j.ccr.2005.01.027.
7
Cancer statistics, 2005.
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30. doi: 10.3322/canjclin.55.1.10.
9
Toll-dependent control mechanisms of CD4 T cell activation.
Immunity. 2004 Nov;21(5):733-41. doi: 10.1016/j.immuni.2004.10.006.
10
Cancer immunotherapy: moving beyond current vaccines.
Nat Med. 2004 Sep;10(9):909-15. doi: 10.1038/nm1100.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验